Karolin Isaksson

Medicon Village
Lund, M 22185, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 80 publications

Impact of occult metastasis size on mortality in stage IIIA melanoma: a Swedish population-based registry study.

Impact of occult metastasis size on mortality in stage IIIA melanoma: a Swedish population-based registry study.

Journal: The British journal of dermatology

Published: April 19, 2026

Declining melanoma incidence among younger adults in Sweden: insights from histopathological subtypes and the role of immigration.

Declining melanoma incidence among younger adults in Sweden: insights from histopathological subtypes and the role of immigration.

Journal: Acta oncologica (Stockholm, Sweden)

Published: April 08, 2026

Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III-IV melanoma: A retrospective cohort study.

Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III-IV melanoma: A retrospective cohort study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 24, 2026

Neoadjuvant immunotherapy for resectable cutaneous melanoma: a nationwide population-based cohort.

Neoadjuvant immunotherapy for resectable cutaneous melanoma: a nationwide population-based cohort.

Journal: Journal of the National Cancer Institute

Published: March 11, 2026

Comment on 'Contrasting Survival Outcomes and Patient Characteristics in 5,815 Patients with Stage II and III Melanoma: A Nationwide Population-Based Registry Study from Sweden': reply from authors.

Comment on 'Contrasting Survival Outcomes and Patient Characteristics in 5,815 Patients with Stage II and III Melanoma: A Nationwide Population-Based Registry Study from Sweden': reply from authors.

Journal: The British journal of dermatology

Published: February 13, 2026

Neoadjuvant Immunotherapy Using PD-1 Inhibitors for Resectable Stage III Cutaneous Melanoma-Different Outcomes Between Patients With Lymph Node and In-transit Metastases.

Neoadjuvant Immunotherapy Using PD-1 Inhibitors for Resectable Stage III Cutaneous Melanoma-Different Outcomes Between Patients With Lymph Node and In-transit Metastases.

Journal: Annals of surgery

Published: February 06, 2026

The Effects of Sun Exposure and Pigmentation Phenotype on Prognosis in Metastatic Melanoma.

The Effects of Sun Exposure and Pigmentation Phenotype on Prognosis in Metastatic Melanoma.

Journal: Acta dermato-venereologica

Published: January 29, 2026

Evaluating COVID-19 Pandemic Impact on Melanoma Incidence and factors in Regions with Different Infection Control Strategies.

Evaluating COVID-19 Pandemic Impact on Melanoma Incidence and factors in Regions with Different Infection Control Strategies.

Journal: The British journal of dermatology

Published: December 23, 2025

SWE-NEO: Swedish NEO-adjuvant trial comparing anti-PD-1 monotherapy to combined anti-CTLA-4/anti-PD-1 blockade in resectable stage III melanoma: study protocol for a phase III open-label multi-centre trial.

SWE-NEO: Swedish NEO-adjuvant trial comparing anti-PD-1 monotherapy to combined anti-CTLA-4/anti-PD-1 blockade in resectable stage III melanoma: study protocol for a phase III open-label multi-centre trial.

Journal: Acta oncologica (Stockholm, Sweden)

Published: December 17, 2025

Weight trajectories and obesity onset between 17 and 60 years of age, and cause-specific mortality: the Obesity and Disease Development Sweden (ODDS) pooled cohort study.

Weight trajectories and obesity onset between 17 and 60 years of age, and cause-specific mortality: the Obesity and Disease Development Sweden (ODDS) pooled cohort study.

Journal: EClinicalMedicine

Published: November 03, 2025

Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study.

Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 15, 2025

Modeling anti-tumor immune responses using patient-derived melanoma organoids.

Modeling anti-tumor immune responses using patient-derived melanoma organoids.

Journal: Cancer immunology, immunotherapy : CII

Published: August 29, 2025

Showing 1-12 of 80

Last Updated: 09/26/2026